GlyNAC has been found to enhance mitochondrial biogenesis, improve energy metabolism, and reduce oxidative stress
IV Efficacy: Intravenous (IV) administration, which bypasses the digestive system, has demonstrated efficacy in specific clinical settings
Obesity, a state of excess fat storage, is associated with an increased risk of a number of chronic diseases, including high blood pressure, type 2 diabetes mellitus, liver and gallbladder disease, osteoarthritis, sleep apnea, and certain cancers
resbiotic makes this distinction clear on their packaging and marketing materials, though the name "GLP-1 Postbiotic" understandably creates confusion for people who associate GLP-1 with medications like compounded semaglutide or compounded tirzepatide